A Prospective, Multicenter Exploratory Clinical Study on Consolidation Therapy With Tislelizumab Combined With Nintedanib for Limited-stage Small Cell Lung Cancer

This study is a prospective, single-arm, multicenter, exploratory clinical trial. It aims to evaluate the efficacy and safety of tislelizumab combined with nintedanib as consolidation therapy for patients with limited-stage small cell lung cancer after concurrent chemoradiotherapy, and to explore the prognostic markers related to the therapeutic effect.

NCT Number	NCT07485920
Lead Sponsor	The Affiliated Hospital of Qingdao University
Conditions	Limited-stage Small Cell Lung Cancer (LS-SCLC)
Enrollment	20 participants
Start Date	2026-05-01
Primary Completion	2028-12-10 (estimated)
Study Completion	2030-01-31 (estimated)
Updated on ClinicalTrials.gov	2026-03-20